SEARCH:   Advanced

Blood, 15 August 2004, Vol. 104, No. 4, pp. 1224-1226. Prepublished online as a Blood First Edition Paper on April 27, 2004; DOI 10.1182/blood-2004-01-0028. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0028v1 104/4/1224    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ho, V. T. Articles by Antin, J. H. Search for Related Content PubMed PubMed Citation Articles by Ho, V. T. Articles by Antin, J. H. Related Collections Immunobiology Transplantation Immunotherapy Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief report Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Vincent T. Ho, David Zahrieh, Ephraim Hochberg, Eileen Micale, Jesse Levin, Carol Reynolds, Steve Steckel, Corey Cutler, David C. Fisher, Stephanie J. Lee, Edwin P. Alyea, Jerome Ritz, Robert J. Soiffer, and Joseph H. Antin From the Divisions of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Ligand Pharmaceuticals, Inc, San Diego, CA; and Harvard Medical School, Boston MA. Denileukin diftitox (Ontak), a recombinant protein composed of human interleukin 2 (IL-2) fused to diphtheria toxin, has selective cytotoxicity against activated lymphocytes expressing the high-affinity IL-2 receptor. We conducted a phase 1 study of denileukin diftitox in 30 patients with steroid refractory acute graft-versus-host disease (GVHD). Seven patients received 9 µg/kg intravenously on days 1 and 15; 18 received 9 µg/kg intravenously on days 1, 3, 5, 15, 17, and 19; and 5 received 9 µg/kg intravenously on days 1 to 5 and 15 to 19. Hepatic transaminase elevation was the dose-limiting toxicity (DLT), and dose level 2 was the maximum tolerated dose (MTD). Overall, 71% of patients responded with complete resolution (12 of 24; 50%) or partial resolution (5 of 24; 21%) of GVHD. Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD. (Blood. 2004;104:1224-1226) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. S Kim Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation Ann. Pharmacother., September 1, 2007; 41(9): 1436 - 1444. [Abstract] [Full Text] [PDF] H. J. Deeg How I treat refractory acute GVHD Blood, May 15, 2007; 109(10): 4119 - 4126. [Abstract] [Full Text] [PDF] J. Vieweg, Z. Su, P. Dahm, and S. Kusmartsev Reversal of Tumor-Mediated Immunosuppression Clin. Cancer Res., January 15, 2007; 13(2): 727s - 732s. [Abstract] [Full Text] [PDF] D. Weisdorf GVHD The Nuts and Bolts Hematology, January 1, 2007; 2007(1): 62 - 67. [Abstract] [Full Text] [PDF] F. Ghori, K. D. Polder, L. C. Pinter-Brown, A. O. Hoff, R. F. Gagel, S. I. Sherman, and M. Duvic Thyrotoxicosis after Denileukin Diftitox Therapy in Patients with Mycosis Fungoides J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2205 - 2208. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020